Securian Asset Management Inc. Sells 189 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Securian Asset Management Inc. cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.6% in the 4th quarter, HoldingsChannel reports. The firm owned 7,221 shares of the biotechnology company’s stock after selling 189 shares during the period. Securian Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $878,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Wellington Management Group LLP lifted its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC lifted its position in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Sarepta Therapeutics by 9.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after purchasing an additional 63,437 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Sarepta Therapeutics during the third quarter valued at approximately $79,425,000. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on SRPT shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective for the company. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Royal Bank of Canada lowered their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Scotiabank started coverage on shares of Sarepta Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective for the company. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.41.

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $97.19 on Friday. Sarepta Therapeutics, Inc. has a 12 month low of $97.06 and a 12 month high of $173.25. The stock has a market cap of $9.43 billion, a PE ratio of 77.75 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company’s fifty day moving average price is $111.73 and its 200-day moving average price is $119.96.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.